Literature DB >> 23952195

Meta-analysis: pharmacological treatment of pathological gambling.

Christine A Bartley1, Michael H Bloch.   

Abstract

BACKGROUND: This meta-analysis investigates the efficacy of pharmacological treatments for pathological gambling (PG).
METHODS: We searched for randomized, placebo-controlled trials examining pharmacotherapy of pathological gamblers. A fixed-effects model was used to calculate the standardized mean difference (SMD) of the benefit of medication (stratified by class) compared to placebo. Secondary analyses examined the effects of publication bias, year of publication and adherence to intention-to-treat (ITT) principles on reported efficacy of interventions.
RESULTS: Meta-analysis included 14 trials involving 1024 participants. Opiate antagonists demonstrated a small but significant benefit compared to placebo (SMD = 0.22 ± 0.10 (95% CI: 0.03-0.41), z = 2.3, p = 0.02). The reported efficacy of opiate antagonists was significantly associated with non-adherence to ITT principles in trials and earlier year of publication. Other medications had non-significant effect sizes compared to placebo but similar in magnitude to opiate antagonists.
CONCLUSIONS: Current trial data provides limited support for the use of any pharmacological agent in the treatment of pathological gambling.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23952195     DOI: 10.1586/14737175.2013.814938

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  13 in total

1.  Gambling Disorder: Exploring Pre-treatment and In-treatment Dropout Predictors. A UK Study.

Authors:  Silvia Ronzitti; Emiliano Soldini; Neil Smith; Massimo Clerici; Henrietta Bowden-Jones
Journal:  J Gambl Stud       Date:  2017-12

Review 2.  Gambling disorder: an integrative review of animal and human studies.

Authors:  Katherine M Nautiyal; Mayumi Okuda; Rene Hen; Carlos Blanco
Journal:  Ann N Y Acad Sci       Date:  2017-04       Impact factor: 5.691

Review 3.  Pharmacological interventions for the treatment of disordered and problem gambling.

Authors:  Nicki Dowling; Stephanie Merkouris; Dan Lubman; Shane Thomas; Henrietta Bowden-Jones; Sean Cowlishaw
Journal:  Cochrane Database Syst Rev       Date:  2022-09-22

4.  Clinical and Research Implications of Gambling Disorder in DSM-5.

Authors:  Jeremiah Weinstock; Carla J Rash
Journal:  Curr Addict Rep       Date:  2014-06-13

5.  Dopamine and Gambling Disorder: Prospects for Personalized Treatment.

Authors:  Andrew Kayser
Journal:  Curr Addict Rep       Date:  2019-03-07

Review 6.  An overview of gambling disorder: from treatment approaches to risk factors.

Authors:  José M Menchon; Gemma Mestre-Bach; Trevor Steward; Fernando Fernández-Aranda; Susana Jiménez-Murcia
Journal:  F1000Res       Date:  2018-04-09

Review 7.  Treatment modalities for patients with gambling disorder.

Authors:  Sam-Wook Choi; Young-Chul Shin; Dai-Jin Kim; Jung-Seok Choi; Seohee Kim; Seung-Hyun Kim; HyunChul Youn
Journal:  Ann Gen Psychiatry       Date:  2017-04-28       Impact factor: 3.455

8.  Food Addiction in Gambling Disorder: Frequency and Clinical Outcomes.

Authors:  Susana Jiménez-Murcia; Roser Granero; Ines Wolz; Marta Baño; Gemma Mestre-Bach; Trevor Steward; Zaida Agüera; Anke Hinney; Carlos Diéguez; Felipe F Casanueva; Ashley N Gearhardt; Anders Hakansson; José M Menchón; Fernando Fernández-Aranda
Journal:  Front Psychol       Date:  2017-04-04

Review 9.  Pharmacological Treatments for Disordered Gambling: A Meta-analysis.

Authors:  Martina Goslar; Max Leibetseder; Hannah M Muench; Stefan G Hofmann; Anton-Rupert Laireiter
Journal:  J Gambl Stud       Date:  2019-06

10.  Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers.

Authors:  Inge Mick; Jim Myers; Anna C Ramos; Paul R A Stokes; David Erritzoe; Alessandro Colasanti; Roger N Gunn; Eugenii A Rabiner; Graham E Searle; Adam D Waldman; Mark C Parkin; Alan D Brailsford; José C F Galduróz; Henrietta Bowden-Jones; Luke Clark; David J Nutt; Anne R Lingford-Hughes
Journal:  Neuropsychopharmacology       Date:  2015-11-10       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.